Clarus Therapeutics and Blue Water Acquisition today announced a definitive business combination agreement that values Clarus at $379 million on a fully diluted basis, assuming no redemptions by Blue Water stockholders.
Current Clarus stakeholders will invest an additional $25 million in the therapeutics company following today’s announcement of the transaction.
Subject to stockholder approval, the business combination is expected to close in the third quarter.
Blue Water raised $57.5 million in a December IPO. Read more.
